CITAF dividend yield: 4.00%. MRK dividend yield: 3.25%. CITAF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CITAF shares. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
CITAF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CITAF shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Is CITAF or MRK better for dividend income in 2026?
CITAF currently offers a 4.00% yield (2.00/share/year) while MRK offers 3.25% (3.08/share/year). CITAF provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in CITAF vs MRK earn per year?
With $10,000 invested today: CITAF pays approximately $400/year. MRK pays approximately $325/year. With DRIP reinvestment over 10 years, these grow to $899/year (CITAF) and $950/year (MRK).
Does CITAF or MRK pay monthly dividends?
CITAF pays quarterly dividends. MRK pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this CITAF vs MRK comparison by email
Save your analysis + get weekly dividend insights. Free forever.